

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: markspencer

Timestamp: [year=2008; month=4; day=21; hr=13; min=57; sec=0; ms=383;]

=====

Application No: 10507009 Version No: 2.0

Input Set:

Output Set:

Started: 2008-04-02 16:20:57.494
Finished: 2008-04-02 16:20:58.250
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 756 ms
Total Warnings: 9
Total Errors: 2
No. of SeqIDs Defined: 11
Actual SeqID Count: 11

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
E 257	Invalid sequence data feature in <221> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
E 257	Invalid sequence data feature in <221> in SEQ ID (11)

SEQUENCE LISTING

<110> IOANNIDES, CONSTANTIN G
CAMPBELL, MARTIN A
O'BRIAN, CATHERINE A

<120> CONTROLLED MODULATION OF AMINO ACID SIDE CHAIN LENGTH OF
PEPTIDE ANTIGENS

<130> UTSC:711US

<140> 10507009

<141> 2005-03-28

<150> PCT/US03/06952

<151> 2003-03-06

<150> 60/412,441

<151> 2002-09-20

<150> 60/362,778

<151> 2002-03-08

<160> 11

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

<213> Homo sapiens

<400> 1

Leu Leu Phe Gly Tyr Pro Val Tyr Val

1 5

<210> 2

<211> 9

<212> PRT

<213> Homo sapiens

<400> 2

Lys Ile Phe Gly Ser Leu Ala Phe Leu

1 5

<210> 3

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 3

Gly Ile Phe Gly Ser Leu Ala Phe Leu

1 5

<210> 4

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 4

Lys Ile Phe Gly Ala Leu Ala Phe Leu

1 5

<210> 5

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 5

Lys Ile Phe Gly Gly Leu Ala Phe Leu

1 5

<210> 6

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 6

Lys Ile Phe Gly Lys Leu Ala Phe Leu

1 5

<210> 7

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 7

Lys Ile Phe Ser Gly Ser Leu Ala Lys Leu
1 5 10

<210> 8

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 8

Lys Ile Phe Gly Ser Leu Ala Tyr Leu
1 5

<210> 9

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 9

Lys Ile Phe Gly Ser Leu Ala Asp Leu
1 5

<210> 10

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<220>

<221> modified_res

<222> (7)

<223> xaa = Norleucine

<400> 10

Lys Ile Phe Gly Ser Leu Xaa Phe Leu
1 5

<210> 11

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<220>

<221> modified_res

<222> (8)

<223> xaa = Isophenylalaine

<400> 11

Lys Ile Phe Gly Ser Leu Ala Xaa Leu

1

5